Myriad Gets Phase IIb HIV Maturation Inhibitor From Panacos For $7M
This article was originally published in The Pink Sheet Daily
Executive Summary
Soon to split from parent Myriad Genetics, biotech obtains compound from Panacos without milestone or royalty obligations.